Status:
ACTIVE_NOT_RECRUITING
Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
Lead Sponsor:
Partha Basu
Collaborating Sponsors:
All India Institute of Medical Sciences
Cancer Foundation of India
Conditions:
Cervical Cancer
Cervical Precancerous Lesions
Eligibility:
FEMALE
10-18 years
Phase:
PHASE4
Brief Summary
The primary study hypothesis wasthat a two-dose human papillomavirus (HPV) vaccine regimen would offer similar immunogenicity and protection as that of a three-dose regimen to girls against persistent...
Detailed Description
The suspension of vaccination resulted in girls receiving 3 doses (days 1, 60 and ≥180), receiving 2 doses (days 1 and ≥180), receiving 2 doses at days 1 and 60 due to incomplete treatment ("by defaul...
Eligibility Criteria
Inclusion
- Apparently healthy, ambulant girls aged 10 - 18 years
- Unmarried girls
- Girls with intact uterus
- Resident in the villages chosen for the study
Exclusion
- Girls with any severe and/or debilitating illness
- Past history of allergy to any medication
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2026
Estimated Enrollment :
22729 Patients enrolled
Trial Details
Trial ID
NCT00923702
Start Date
September 1 2009
End Date
July 1 2026
Last Update
September 28 2023
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
MNJ Institute of Oncology & Regional Cancer Center
Hyderabad, Andhra Pradesh, India, 500004
2
Gujarat Cancer & Research Institute (GCRI)
Ahmedabad, Gujarat, India, 380 016
3
Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital
Barshi, Maharashtra, India, 413 401
4
Tata Memorial Center, Tata Memorial Hospital & Cancer Research Inst
Mumbai, Maharashtra, India, 400 012